Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-07-11
2006-07-11
Minnifield, N. M. (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S023400, C435S320100, C435S252100, C435S069300, C435S071100
Reexamination Certificate
active
07074913
ABSTRACT:
The present invention relates to mammalian anthrax toxin receptor polypeptides and polynucleotides encoding same as well as related polypeptides and polynucleotides, vectors containing the polynucleotides and polypeptides, host cells containing related polynucleotide molecules, and cells displaying no anthrax toxin receptor on an exterior surface of the cells-minus cell lines and animals. The present invention also relates to methods for identifying molecules that bind the anthrax toxin receptor and molecules that reduce the toxicity of anthrax toxin. Finally, the present invention provides methods for treating human and non-human animals suffering from anthrax.
REFERENCES:
patent: 5591631 (1997-01-01), Leppla et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 6022855 (2000-02-01), Thomas et al.
patent: 6329156 (2001-12-01), Cirino et al.
patent: 6485925 (2002-11-01), Duesbery et al.
patent: 6569662 (2003-05-01), Tang et al.
patent: 6592872 (2003-07-01), Klimpel et al.
patent: 2002/0039588 (2002-04-01), Collier et al.
patent: 2002/0048590 (2002-04-01), Klimpel et al.
patent: 2002/0051791 (2002-05-01), Galloway et al.
patent: 2002/0142002 (2002-10-01), Galloway et al.
patent: 2002/0197272 (2002-12-01), Galloway et al.
patent: 2003/0003109 (2003-01-01), Galloway et al.
patent: 2003/0096333 (2003-05-01), Duesbery et al.
patent: 2003/0108556 (2003-06-01), Mekalanos et al.
patent: 2003/0119720 (2003-06-01), Khan et al.
patent: 2003/0198651 (2003-10-01), Klimpel et al.
patent: 2003/0202989 (2003-10-01), Collier et al.
patent: 2005/0196407 (2005-09-01), Young et al.
patent: WO 00/39284 (2000-07-01), None
patent: WO 01/34626 (2001-05-01), None
patent: WO 01/53312 (2001-07-01), None
patent: WO 01/77137 (2001-10-01), None
patent: WO 02/10217 (2002-02-01), None
patent: WO 02/46228 (2002-06-01), None
Pannifer et al Nature, 414:229-233 Nov. 8, 2001.
Bradley et al Nature, 414:255-228 Nov. 8, 2001.
Benson et al, Biochemistry 37:3941-48; 1998.
Elliott et al, Biochemistry, 39:6706-6713; 2000.
Cunningham et al, PNAS 99/10: 7049-53, 2002.
Kumar et al, Infection & Immunity 69/10:6532-36, 2001.
Chauhan et al, Infection & Immunity 70/8:4477-84, 2002.
Mogridge et al, J. Bacteriology 183/6:2111-116, 2001.
St. Croix et al, Science, 289:1197-1202, 2000.
NCBI; GenBank Accession# BC012074, 2001.
Accession# AF421380, 2001.
Accession# AF279145, 2001.
Accession# AAD05303, 2001.
Batra et al, BBRC 281:186-192, 2001.
Zhao et al, JBC, 270/31:18626-630, 1995.
Milne et al, Mol. Microbiol. 15/4:661-666, 1995.
Mourez et al, Trends in Microbiology 10/6:287-93, 2002.
Brossier et al, Toxicon, 2001; 39:1747-1755.
Chaudry et al, TRENDS in Microbiology, Feb. 2002, 10/2:58-62.
Moayeri et al, Current Opinion in Microbiology, 2004, 7:19-24.
Abrami et al, TRENDS in Microbiology, Feb. 2005, 13/2:72-78.
Laird et al, Proetin Expression and Purification, 2004, 38:145-152.
Mourez et al, TRENDS in Microbiology, Jun. 2002, 10/6:287-293.
Bradley et al, Biochemical Pharmacology, 2003, 65:309-314.
Lacey et al, Current Topics Microbiol. Immunol., 2002, 271:61-85.
Beauregard, et al., “Anthrax Toxin Entry into Polarized Epithelial Cells,”Infection and Immunity67:3026-3030 (1999).
Boerger, et al., “Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types,”Proc. Natl. Acad. Sci. USA96:9867-9872 (1999).
Dickeson, et al., “Ligand recognition by the I domain-containing integrins,”CMLS Cell. Mol. Life Sci.54:556-566 (1998).
Elliott, Jennifer, “Assembly and Translocation of Anthrax Toxin,” Ph.D. Thesis, Department of Microbiology (Cambridge, MA, Harvard University) pp. 35-65 (1998).
Escuyer, et al., “Anthrax Protective Antigen Interacts with a Specific Receptor on the Surface of CHO-K1 Cells,”Infection and Immunity59:3381-3386 (1991).
Genbank Accession No. AK001463, “Homo sapiens cDNA FLJ10601 fis, clone NT2RP2005000,”NCB1 Sequence Viewer2 pages (Sep. 28, 2001).
Genbank Accession No. BC012074, “Homo sapiens, similar to tumor endothelial marker 8, clone MGC:19967 IMAGE:4563020, mRNA, complete cds,”NCB1 Sequence Viewer2 pages (Sep. 25, 2001).
Genbank Accession No. NM—032208, “Homo sapiens tumor endothelial marker 8 (TEM8), mRNA,”NCB1 Sequence Viewer3 pages (Nov. 2, 2001).
Gordon, et al., “Inhibitors of Receptor-Mediated Endocytosis Block the Entry ofBacillus anthracisAdenylate Cyclase Toxin but Not That ofBordetella pertussisAdenylate Cyclase Toxin,”Infection and Immunity56:1066-1069 (1988).
Hanna, et al., “On the role of macrophages in anthrax,”Proc. Natl. Acad. Sci. USA90:10198-10201 (1993).
Hanna, P., “Anthrax Pathogenesis and Host Response,”Current Topics in Microbiology and Immunology225:13-35 (1998).
Klimpel, et al., “Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin,”Proc. Natl. Acad. Sci. USA89:10277-10281 (1992).
Lee, et al., “Crystal Structure of the A Domain from the α Subunit of Integrin CR3 (CD11b/CD18),”Cell80:631-638 (1995).
Leppla, Stephan A., “The bifactorialBacillus anthracislethal and oedema toxins,”The Comprehenisiv Sourcebook of Bacterial Protein ToxinsChapter 12:243-263 (1999).
Menard, et al., “The Vacuolar ATPase proton pump is required for the cytotoxicity ofBacillus anthracislethal toxin,”FEBS Letters386:161-164 (1996).
Miller, et al., “Anthrax Protective Antigen: Prepore-to-Pore Conversion,”Biochemistry38:10432-10441 (1999).
Milne, et al., “Anthrax Protective Antigen Forms Oligomers during Intoxication of Mammalian Cells,”The Journal of Biological Chemistry269:20607-20612 (1994).
Petosa, et al., “Crystal structure of the anthrax toxin protective antigen,”Letters to Nature385:833-838 (1997).
Snitkovsky et al, “Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein,”Proc. Natl. Acad. Sci. USA96:7063-7068 (1998).
Snitkovsky, et al., “A TVA-Single-Chain Antibody Fusion Protein Mediates Specific Targeting of a Subgroup A Avian Leukosis Virus Vector to Cells Expressing a Tumor-Specific Form of Epidermal Growth Factor Receptor,”Journal of Virology74:9540-9545 (2000).
Snitkovsky, et al, “Targeting Avian Leukosis Virus Subgroup A Vectors by Using a TVA-VEGF Bridge Protein,”Journal of Virology75:1571-1575 (2001).
Croix, et al., “Genes Expressed in Human Tumor Endothelium,”Science289:1197-1202 (2000).
Zamore, Philip D., “RNA interference: listening to the sound of silence,”Nature Structural Biology8:746-750 (2001).
Holtzman, D.A., “Human TANGO 197 Coding Sequence,” EMBL Accession #AAA47455 (2000).
Leppla, et al. “Isolation and Characterization of Chinese Hamster Ovary Cell Mutants Lacking the Receptor for Anthrax Toxin Protective Antigen,” Bacterial protein Toxins, Zbl. Bakt. Suppl. 28 (1996).
Rosen, et al., “Human Albumin Fusion Protein #549,” EMBL Accession #ABG63874 (2002).
Ruben, et al., “Human Gene 4 Encoded Secreted Protein HWLFR02, SEQ ID No.:94,” EMBL Accession #AAE01439 (2001).
Ruben, et al., “Human Secreted Protein-Encoding-Encoding Gene 4 cDNA Clone HWLFR02, SEQ ID No.:14,” EMBL Accession #AAD05303 (2001).
St. Croix, et al., “Human Tumour Endothelial Marker Polypeptide SEQ IDNO:232,” EMBL Accession #ABB90750 (2002).
St. Croix, et al., “Human Tumour Endothelial Marker Polynucleotide SEQ ID No.:231,” EMBL Accession #ABL92104 (2002).
Tang, et al., “Human Polypeptide SEQ ID No.:2121,” EMBL Accession #AAM38976 (2001).
Tang, et al., “Human Polynucleotide SEQ ID No.:335,” EMBL Accession #AAI58132 (2001).
Bradley Kenneth A
Collier R. John
Mogridge Jeremy S.
Young John A. T.
Minnifield N. M.
President and Fellows of Harvard College
Quarles & Brady LLP
Wisconsin Alumni Research Foundation
LandOfFree
Receptor for B anthracis toxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Receptor for B anthracis toxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Receptor for B anthracis toxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3575688